Valeant Pharmaceuticals: Ackman Ups Stake, ValueAct Digs In

HFA Padded
Rupert Hargreaves
Published on
Updated on
Michael Pearson Valeant VRX Bill Ackman Pershing Square activism

Valeant Pharmaceuticals still has plenty of supporters despite the media storm surrounding the company and its businesses practices. Last night it emerged that Bill Ackman, one of Valeant’s most staunch supporters, has upped Pershing Square’s stake in Valeant to 9.9% of the company’s outstanding shares — a near 70% increase in Pershing’s holding before recent declines. Pershing Square Ups Valeant Stake Explained In A Few Charts Bill Ackman’s Pershing Square is now Valeant Pharmaceuticals’ second largest shareholder Bill Ackman’s Pershing Square is now Valeant’s second largest shareholder after the Sequoia Fund, which is run by Ruane, Cuniff & Goldfarb. The Sequoia Fund…

This content is exclusively for paying members of Hedge Fund Alpha

Log In

Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha

Don’t have an account?

Subscribe now and get 7 days free!

HFA Padded

Sign up now and get our in-depth FREE e-books on famous investors like Klarman, Dalio, Schloss, Munger Rupert is a committed value investor and regularly writes and invests following the principles set out by Benjamin Graham. He is the editor and co-owner of Hidden Value Stocks, a quarterly investment newsletter aimed at institutional investors. Rupert owns shares in Berkshire Hathaway. Rupert holds qualifications from the Chartered Institute For Securities & Investment and the CFA Society of the UK. Rupert covers everything value investing for ValueWalk